research 1153 ERECTILE HEMODYNAMICS ASSESSMENT IN MEN WITH PERSISTENT ERECTILE DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE
Persistent ED in Propecia users is not due to abnormal blood flow.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch 5alpha-reductase inhibitors/finasteride.
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
research Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
research IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
IsoPSA test works accurately even if patients take certain prostate medications.
research Re: Inhibitors of 5α-Reductase-Related Side Effects in Patients Seeking Medical Care for Sexual Dysfunction
research Finasteride and the 5-Alpha Reductase Inhibitors
research Finasteride: a 5 alpha-reductase inhibitor.
research Finasteride-related Peyronie’s disease
research Re: Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-Reductase inhibitors can negatively impact sexual function.
research 5α‐Reductase Inhibitors
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.
Finasteride increases CD8+ T cells in BPH tissues.
research Trimodal Mini‐Invasive Therapy for Stable‐Phase Peyronie's Disease: A Two‐Center Real‐Life Prospective Pilot Study
PRP injections are safe but don't significantly improve Peyronie's Disease.
research 5α-reductase activity in the prostate
Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
research Experimental Assessment of 3-<i>meta</i>-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors <i>in silico</i> and <i>in vivo</i> Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
research Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
research Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease
Prostaglandin E2 affects human platelet activity in complex ways that could lead to personalized heart disease treatments.
research Selective non-steroidal inhibitors of 5α-reductase type 1
Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
research Оптимизация подходов консервативной терапии доброкачественной гиперплазии предстательной железы ингибиторами 5-альфаредуктазы. Клинико-морфологическое исследование
5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.
research 5 Alpha-reductase inhibitors: whatʼs new?
A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
research Finasteride: the first 5 alpha-reductase inhibitor.
research 15-Hydroxyprostaglandin Dehydrogenase Inhibitor Restores Endothelial Function Under Dihydrotestosterone-Induced Stress in Human Dermal Microvascular Endothelial Cells
DPP may help hair regrowth by improving blood vessel function under stress.
research Identification of Metabolites for the Novel 5α‐Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing
Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
research MP45-12 CHRONIC ADMINISTRATION OF A LIMK2 INHIBITOR IMPROVES CAVERNOSAL VENO-OCCLUSIVE DYSFUNCTION THROUGH SUPPRESSION OF CAVERNOSAL FIBROSIS IN A RAT MODEL OF ERECTILE DYSFUNCTION AFTER CAVERNOSAL NERVE INJURY
Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
research Attenzione divisa nei pazienti con cerebrolesione acquisita
Finasteride may cause sexual and psychological side effects by affecting an enzyme related to epinephrine.
research PD49-02 MEDICATIONS MOST COMMONLY ASSOCIATED WITH ERECTILE DYSFUNCTION: EVALUATION OF THE FOOD AND DRUG ADMINISTRATION NATIONAL PHARMACOVIGILANCE DATABASE
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research HP-01-004 Histomorphometrical Evaluation of The Corpus Cavernosum of Hypertensive Rats Treated with 5-Alpha-Reductase Inhibitors
5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
research A Review on Steroidal 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
research Platelet-rich plasma for erectile dysfunction: a review of the current research landscape
The effectiveness of platelet-rich plasma for erectile dysfunction is still unclear.